Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS other · 2026-01-20Clinical Trial Update: Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting [NA]
A clinical trial update describes a pediatric study evaluating hypnotherapy to manage needle-related pain and anxiety during procedures; the…
-
FDA approval · 2026-01-14FDA Approved: AVTOZMA — Supplemental Application (CELLTRION USA, Inc.)
FDA approves a supplemental application for AVTOZMA (tocilizumab) filed by Celltrion USA, Inc.
-
CLINICAL_TRIALS withdrawal · 2026-01-07Clinical Trial Update: HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis [Phase 2]
Phase 2 trial evaluating HB-adMSCs versus placebo for Juvenile Idiopathic Arthritis has been withdrawn. No results are reported.
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Feasibility of a Diet Intervention for Juvenile Arthritis [NA]
A clinical trial is evaluating the feasibility of a diet intervention for juvenile arthritis and is currently recruiting.
-
EMA approval · 2025-12-16EMA Authorised: Erelzi (etanercept) — Sandoz GmbH
The EMA authorised Erelzi (etanercept) by Sandoz GmbH as a biosimilar to treat several inflammatory conditions including rheumatoid arthriti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT [Phase 2]
Phase 2 study evaluating reduced-intensity conditioning for non-malignant disorders undergoing umbilical cord blood transplantation (UCBT), …
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) [Phase 1]
An early-phase study update noting that the trial to measure filgotinib in the blood of children and adolescents with juvenile idiopathic ar…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Dynamic Gait Index as a Functional Gait Assessment Measure in Children With JIA
A clinical trial evaluating Dynamic Gait Index as a functional gait assessment for children with Juvenile Idiopathic Arthritis, currently re…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Tofacitinib in Juvenile Idiopathic Arthritis
A clinical trial update indicates a study of tofacitinib for juvenile idiopathic arthritis is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA [Phase 2]
A Phase 2 trial evaluating transcutaneous cervical vagus nerve stimulation for juvenile idiopathic arthritis has been terminated; results ha…
-
EMA approval · 2025-11-20EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
The EMA authorised Gobivaz (golimumab) for multiple inflammatory diseases. Indications include rheumatoid arthritis, juvenile idiopathic art…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis [NA]
Clinical trial update on the effective dose of etanercept in patients with Juvenile Idiopathic Arthritis.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic Arthritis [NA]
This clinical trial compares structured core stabilization training to exergaming-based core stabilization in children with Juvenile Idiopat…
-
FDA approval · 2025-10-28FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for RENFLEXIS (infliximab) submitted by Organon LLC. The approval updates the product labeling to re…
-
EMA approval · 2025-10-22EMA Authorised: Amsparity (adalimumab) — Pfizer Europe MA EEIG
EMA authorised Amsparity (adalimumab) from Pfizer Europe MA EEIG. The biosimilar is approved for multiple autoimmune indications including r…
-
FDA approval · 2025-10-17FDA Approved: HADLIMA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HADLIMA (adalimumab-bwwd) from Organon LLC, supporting expanded indications for this adalimumab …
-
FDA approval · 2025-10-16FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) filed by Pfizer Laboratories Div Pfizer Inc, resulting in changes to t…
-
FDA approval · 2025-10-16FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for Amjevita (adalimumab-atto) submitted by Nuvaila Limited.
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Pain in Juvenile Arthritis [NA]
The clinical trial studying pain in Juvenile Idiopathic Arthritis is currently recruiting; sponsor is Washington University School of Medici…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity [NA]
This document provides an update on a rheumatology-focused clinical trial sponsored by Brigham and Women's Hospital that studies an adaptive…
-
EMA approval · 2025-10-13EMA Authorised: Ilaris (Canakinumab) — Novartis Europharm Limited
The EMA authorised Ilaris (canakinumab) for use in Cryopyrin-Associated Periodic Syndromes, juvenile idiopathic arthritis, and gout.
-
EMA approval · 2025-10-08EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Humira (adalimumab) by AbbVie Deutschland GmbH & Co. KG for multiple indications including ankylosing spondylitis, juveni…
-
FDA approval · 2025-10-03FDA Approved: NAPROXEN — Original Application (Aurobindo Pharma Limited)
FDA approved Naproxen from Aurobindo Pharma Limited as an original generic application (ANDA 216504). Naproxen is a nonsteroidal anti-inflam…
-
EMA approval · 2025-10-02EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Tyenne (tocilizumab) by Fresenius Kabi Deutschland GmbH for multiple indications, including rheumatoid arthritis, juvenile id…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
An observational registry evaluating abatacept in patients with Juvenile Idiopathic Arthritis, sponsored by Bristol-Myers Squibb. The study …